Wedbush Maintains Miragen Therapeutics Inc (MGEN) As a “Buy”; They Now Have a TP Of $19.0000

June 8, 2018 - By Linda Rogers

Miragen Therapeutics Inc (MGEN) Rating Reaffirmed

Wedbush now has a $19.0000 PT on shares of Miragen Therapeutics Inc (MGEN). The PT suggests a potential upside of 155.38 % from the close price of Miragen Therapeutics Inc (MGEN). This rating was disclosed to clients in a research report on Thursday morning.

Miragen Therapeutics, Inc. (NASDAQ:MGEN) Ratings Coverage

Among 7 analysts covering miRagen Therapeutics Inc (MGEN), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. miRagen Therapeutics Inc has $19 highest and $1300 lowest target. $16.29’s average target is 118.95% above currents $7.44 stock price. miRagen Therapeutics Inc had 19 analyst reports since January 4, 2018 according to SRatingsIntel. Wedbush initiated the stock with “Buy” rating in Wednesday, March 28 report. Oppenheimer initiated it with “Buy” rating and $1300 target in Tuesday, March 27 report. The firm has “Buy” rating by FBR Capital given on Friday, February 2. FBR Capital maintained Miragen Therapeutics, Inc. (NASDAQ:MGEN) on Thursday, May 17 with “Buy” rating. The firm has “Buy” rating by FBR Capital given on Tuesday, March 27. The stock of Miragen Therapeutics, Inc. (NASDAQ:MGEN) earned “Buy” rating by FBR Capital on Thursday, March 15. Oppenheimer initiated Miragen Therapeutics, Inc. (NASDAQ:MGEN) on Thursday, January 11 with “Buy” rating. The stock has “Buy” rating by Wedbush on Wednesday, May 16. The stock of Miragen Therapeutics, Inc. (NASDAQ:MGEN) has “Buy” rating given on Tuesday, March 20 by Wedbush. On Monday, April 23 the stock rating was maintained by Wedbush with “Buy”.

The stock decreased 0.67% or $0.05 during the last trading session, reaching $7.44. About 145,017 shares traded. Miragen Therapeutics, Inc. (MGEN) has declined 34.18% since June 8, 2017 and is downtrending. It has underperformed by 46.75% the S&P500.

Analysts await Miragen Therapeutics, Inc. (NASDAQ:MGEN) to report earnings on August, 10. They expect $-0.29 EPS, up 14.71 % or $0.05 from last year’s $-0.34 per share. After $-0.18 actual EPS reported by Miragen Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 61.11 % negative EPS growth.

Miragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. The company has market cap of $224.63 million. The Company’s two lead product candidates, MRG-106 and MRG-201 are in Phase 1 clinical trials. It currently has negative earnings. The companyÂ’s clinical product candidate for the treatment of certain cancers, MRG-106, is an inhibitor of microRNA-155, which is found at abnormally high levels in various blood cancers.

More important recent Miragen Therapeutics, Inc. (NASDAQ:MGEN) news were published by: Seekingalpha.com which released: “miRagen Therapeutics’ (MGEN) CEO William Marshall on Q1 2018 Results – Earnings Call Transcript” on May 10, 2018, also Nasdaq.com published article titled: “miRagen Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update”, Nasdaq.com published: “miRagen Therapeutics to Present at Jefferies 2018 Global Healthcare Conference on Thursday, June 7th” on May 18, 2018. More interesting news about Miragen Therapeutics, Inc. (NASDAQ:MGEN) was released by: Benzinga.com and their article: “The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines” with publication date: June 03, 2018.

Miragen Therapeutics, Inc. (NASDAQ:MGEN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: